Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 19 September 2023 – 6PM CET Fagron completes share buy-back program Fagron has successfully completed its share buy-back program today. In the last period, from 18 September 2023 through 19 September 2023, Fagron purchased 17,266 of its owns shares at an average price of €16.12 per share corresponding to a total amount of €277,612.81. A total of 138,372 Fagron shares have been repurchased under the buy-back program at an averag
Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 15 September 2023 – 6PM CET Progress share buy-back program Fagron In the period from 11 September 2023 through 15 September 2023, Fagron purchased 27,000 of its owns shares at an average price of €16.81 per share corresponding to a total amount of €453,745.66. These purchases are part of the share buy-back program of up to 138,372 Fagron shares to fulfill Fagron’s obligations under its long term incentive scheme, which was ann
Regulated information – inside informationNazareth (Belgium)/Rotterdam (The Netherlands), 3 August 2023 – 7AM CET Fagron delivers strong performance with 13% topline growth and 14% increase in REBITDA for first half of 2023 Fagron, the leading global player in pharmaceutical compounding today publishes its first half results for the period ending 30 June 2023. Key Highlights Strong topline performance with 13.1% reported revenue growth (12.1% at CER) and 8.4% organic revenue growth at CEROrganic